uniQure N.V. Interest Expense 2011-2026 | QURE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense uniQure N.V.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	41.6 M	2.76 M	7.47 M	3.82 M	3.81 M	2.16 M	2.23 M	2.17 M	2.57 M	2.02 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
41.6 M	2.02 M	7.06 M

Quarterly Interest Expense uniQure N.V.

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-7.22 M	-	-	-	-	-	16.1 M	-	15.4 M	6.84 M	3.56 M	-	3.07 M	2.69 M	2.52 M	-	1.92 M	1.9 M	1.55 M	-	942 K	970 K	975 K	-	960 K	937 K	957 K	-	515 K	565 K	416 K	-	577 K	502 K	504 K	-	507 K	549 K	629 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
16.1 M	-7.22 M	2.26 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	1.11 M	$ 1.9	-3.11 %	$ 107 M	China
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 25.88	-0.73 %	$ 1.25 B	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.31	-4.06 %	$ 7.96 B	Australia
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Aytu BioScience AYTU	-512 K	$ 2.7	1.5 %	$ 17 M	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.9	0.52 %	$ 908 M	Israel
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.96	-1.0 %	$ 8.62 B	Israel
CASI Pharmaceuticals CASI	2.9 K	$ 0.95	-0.72 %	$ 129 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 215.17	4.54 %	$ 5 B	Danmark
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA
Celldex Therapeutics CLDX	927 K	$ 25.17	-1.89 %	$ 1.62 M	USA
Arrowhead Pharmaceuticals ARWR	5.26 M	$ 64.51	1.04 %	$ 8.63 B	USA
Catalyst Pharmaceuticals CPRX	21.1 M	$ 23.24	2.38 %	$ 2.75 B	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 14.0	3.63 %	$ 922 M	USA
Biogen BIIB	250 M	$ 164.49	0.04 %	$ 23.9 B	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
BioVie BIVI	4.3 M	$ 1.24	2.49 %	$ 1.83 M	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA